Recent research from the Van Andel Institute revealed that cancer cells metabolize ketones via a non-canonical route to produce acetyl-CoA, implicating metabolic flexibility in tumor proliferation. Supporting this, first-in-human trials demonstrated promising efficacy of DLL3-targeted antibody-drug conjugates in relapsed SCLC, and novel DNA-PK inhibitors from Juno Therapeutics advance cancer treatment strategies. This body of work underscores emerging potential to disrupt cancer growth by targeting unique metabolic pathways and leveraging precision oncology therapeutics.